Login für Redakteure
Publikationen 2024
Weitere Informationen zu den Publikationen der AG Prof. Sippl finden sie hier:
A. G. Kansy, R. Ashry, A. M. Mustafa, A. Alfayomy, M.P. Radsak, Y. Zeyn, M. Bros, W. Sippl and O. H. Krämer. Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells. Mol Oncol. 2024 Mar 22. doi:10.1002/1878-0261.13638.
A. M. Alfayomy, R. Ashry, A. Kansy, A.C. Sarnow, F. Erdmann, M. Schmidt, O. H. Krämer, W. Sippl. Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the Ataxia telangiectasia and RAD3-related (ATR) kinase. European J Med Chem. 2024, 267:116167. https://doi.org/10.1016/j.ejmech.2024.116167
F. Baselious, S. Hilscher, S. Hagemann, S. Tripathee, D. Robaa, C. Barinka, S. Hüttelmaier, M. Schutkowski, W. Sippl. Utilization of an Optimized AlphaFold Protein Model for Structure-Based Design of a Selective HDAC11 Inhibitor with Anti-neuroblastoma Activity. 10.26434/chemrxiv-2024-6f790
F. Baselious, S. Hilscher, D. Robaa, C. Barinka, M. Schutkowski, W. Sippl. Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 Inhibitor. Int. J. Mol. Sci. 2024, 25(2), 1358; doi.org/10.3390/ijms25021358
M. Pannek, Z. Al Halabi, D. Tomaselli, M. Menna, F. Fiorentino, D. Robaa, M. Weyand, M. Puhlmann, S. Tomassi, F. Barreca, M. Tafani, E. Zaganjor, M. Haigis, W. Sippl, D. Rotili, A. Mai, C. Steegborn. Specific Inhibitors of the Mitochondrial Deacylase Sirtuin 4 Endowed with Cellular Activity. J Med Chem. 2024 67(3):1843-1860. doi:10.1021/acs.jmedchem.3c01496 .
L. Seitz, N. Reiling, C. Vorreiter, W. Sippl, S. Kesselr, A. Hilgeroth.Synthesis and Evaluation of Novel Substituted N-Aryl 1,4-Dihydropyridines as An-tituberculostatic Agents.Med Chem. 20 (1), 30-39, 2024. doi:10.2174/1573406419666230622121512.